Abstract
Avelumab-Induced Scleroderma in a Patient with Metastatic Squamous Cell Carcinoma of the Lung
Case reports in dermatological medicine, Vol.2022, pp.1-3
12/15/2022
DOI: 10.1155/2022/5360113
PMCID: PMC9779987
PMID: 36567751
Abstract
Immune checkpoint inhibitors are associated with a spectrum of cutaneous immune-related adverse events. While maculopapular eruptions are the most common cutaneous adverse event, scleroderma can rarely develop. Herein, we report a case of new-onset scleroderma associated with avelumab treatment in the setting of metastatic squamous cell carcinoma of the lung. The pathophysiology of immune checkpoint inhibitor-induced scleroderma is not completely understood. A proposed mechanism is discussed along with the clinical presentation of symptoms and associated therapeutic response in cancer treatment. This case contributes to the few existing reports of immune checkpoint inhibitor-induced scleroderma to better understand the implications in the management of cutaneous immune-related adverse events.
Details
- Title: Subtitle
- Avelumab-Induced Scleroderma in a Patient with Metastatic Squamous Cell Carcinoma of the Lung
- Creators
- Jeffrey L. Dobrzynski - Roy J. and Lucille A. Carver College of MedicineBlake E. Vest - University of Iowa Hospitals and ClinicsBrian L. Swick - University of Iowa Hospitals and Clinics
- Contributors
- Ioannis D. Bassukas (Editor)
- Resource Type
- Abstract
- Publication Details
- Case reports in dermatological medicine, Vol.2022, pp.1-3
- DOI
- 10.1155/2022/5360113
- PMID
- 36567751
- PMCID
- PMC9779987
- NLM abbreviation
- Case Rep Dermatol Med
- ISSN
- 2090-6463
- eISSN
- 2090-6471
- Language
- English
- Date published
- 12/15/2022
- Academic Unit
- Dermatology; Pathology
- Record Identifier
- 9984353644302771
Metrics
22 Record Views